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Introduction
The mineralocorticoid aldosterone plays a crucial role in the salt and water homeostasis. Its release is mainly controlled by angiotensin-II via the renin-angiotensin-aldosterone system (RAAS) and potassium plasma levels. Chronically elevated plasma aldosterone levels are linked to the development and progression of certain cardiovascular diseases such as hypertension, congestive heart failure, and myocardial fibrosis. The inhibition of CYP11B2 reduces the production of aldosterone and is therefore a treatment option for related diseases.
In the development of CYP inhibitors, a crucial point is the selectivity over other CYP enzymes, especially steroidogenic and hepatic CYPs. The most challenging task is to achieve selectivity versus the highly homologous (> 93% However, in order to avoid the potential impairment of cortisol biosynthesis that could result from CYP11B1 inhibition by this compound, low doses (< 1. 3 In this study, we describe the synthesis and biological properties of a series of 1-phenylsulfinyl-2-hydroxy-3-pyridyl substituted naphthalenes and structurally related compounds (Chart 1). This class of compounds was obtained by oxidation of 1-(phenylthio)-3-(pyridin-3-yl)naphthalen-2-ols, which were readily accessible by a new S N,Ar reaction recently described by us. [ 24 ] The novel compounds revealed themselves as potent and selective CYP11B2 inhibitors. Structure activity relationships of different substituents on the phenylsulfinyl moiety were established considering the potency toward human and the selectivity versus human CYP11B1, CYP17 and CYP19. Compound 11 was further investigated in a pharmacokinetic study in male Wistar rats.
Results

Chemistry.
Recently, the synthesis of sulfides 1a-4a was described by us (Scheme 1). [Fehler:
Referenz nicht gefunden] 2-Methoxynaphthalene is converted into the boronic acid via ortho-lithiation As for the synthesis of compounds 23-24 (Scheme 2), 1-Fluoronaphthalene was first brominated at 3-position in two steps as previously described. 
Biological Results.
The inhibition of human adrenal corticoid producing enzymes CYP11B2 and CYP11B1 was determined in V79MZ cells, stably expressing either human CYP11B2 or CYP11B1 (Table 1) . [6, 36 ] The V79MZ cells were incubated with [ The sulfoxides 1-15 and 17-22 were evaluated for their selectivity versus the steroidogenic enzymes CYP17 and CYP19. Inhibition of CYP17 was determined using the 50,000 g sediment of an E. coli homogenate recombinantly expressing human CYP17 with progesterone as substrate. 38 All compounds demonstrate almost no inhibition (< 5 %) at an inhibitor concentration of 2 μM. The inhibition of CYP19 was evaluated in vitro with human placental microsomes using [1β- (500 nM) as substrate 39 All compounds show hardly any aromatase inhibition (< 5 %) at an inhibitor concentration of 500 nM.
The pharmacokinetic profile of compound 11 was determined by intravenous and per-oral application in a dosage of 1 mg/kg bodyweight to male Wistar rats (3 animals). Plasma samples were collected during 24 h and compound concentrations were determined using HPLC-MS/MS. The compound was fast absorbed after oral application reaching the maximal concentration (c max = 40.4 ng/ml) after 0.5 hours. Terminal half lives were calculated to be 4 hours for intravenous and 7 hours for per-oral application, respectively. Areas under the curve were shown as 1776 and 335 ng·h/ml for intravenous and per-oral application, respectively. Accordingly, bioavailability of 19 % was observed. Phe381 and Phe487 in perpendicular and parallel ways, respectively. An intra-molecular hydrogen bond between the sulfoxide oxygen and the hydroxyl group was observed, which can also be found in the crystal of compound 1 (Figure 2 ). [24] With this intra-molecular hydrogen bond, the compound was folded into a twisted shape, in which the phenyl sulfoxide stretched out perpendicularly with regard to the naphthalenyl core ( Figure 1 ). Such a conformation not only avoided steric clashes with the enzyme, but also facilitated the forming of a π-π interaction between phenyl sulfoxide moiety and Phe130. This observation is in accordance with and well explains the facts that analogues unable to form intramolecular hydrogen bonds (1a-4a, 23 and 24) exhibited low inhibitory potency. Substituents on phenyl sulfoxide moiety were accommodated in a small hydrophobic pocket confined by Met111-Ile112-Leu113-Val117-Leu131, however, no further interactions can be identified, which could be the reason for the observation that compounds with different substituents showed similar potency.
Docking
Discussion and conclusion
This paper describes 1-phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols as a new class of potent and selective human CYP11B2 inhibitors.
3-(Pyridin-3-yl)naphthalene as the common sub-structure of all synthesized compounds has already been shown to be a potent CYP11B2 inhibitor. [20] This fact together with the comparison of the biological results of sulfides 1a-4a (18-22 % inhibition, c = 500 nM) with sulfoxides 1-4 (IC 50 = 27-64 nM) exhibits the importance of the oxygen for CYP11B2 inhibition. Moreover, the hydroxyl group in 2-position seems to be fundamental for the binding affinity. Omission of the hydroxyl group, as accomplished in compound 24, results in a significantly reduced CYP11B2 inhibition of only 33 %.
Both facts could indicate that the intra-molecular hydrogen bridge between the sulfoxide oxygen and the hydroxyl group, as observed in the crystal structure of compound 1 (Figure 2) , [24] still exist after binding to the protein. This hydrogen bond limits steric flexibility and thereby improves the inhibitory potency towards CYP11B2 but not towards other CYP enzymes. In the sulfoxide series the effects of the substituents on the phenyl moiety were investigated (compounds 1-22) . Surprisingly, all tested substituents were found to exhibit strong CYP11B2 inhibition. Only in case of para-cyano substitution, as accomplished in 16 and bioisosteric exchange of phenyl by thiophene (compound 22), there is a sharp loss of inhibitory potency. For the other compounds, no clear structure activity relationship is observed.
The introduction of the electron donating methoxy substituent into the meta-position leads to one of the best compounds of this series (3, IC 50 = 27 nM, SF = 271), whereas a methoxy in para or ortho position results in a significant decrease in selectivity versus CYP11B1 (2, SF = 87 and 4, SF = 17). The same trend was observed after replacing methoxy by trifluoromethoxy, which led to the best compound of this series, i.e. the meta-trifluoromethoxy derivative 11 (IC 50 = 14 nM, SF = 415). Several other electron withdrawing substituents (e.g. ortho-and para-chloro) lead to almost equally potent CYP11B2 inhibitors (7, IC 50 = 22 nM, SF = 204; 5, IC 50 = 22 nM, SF = 407) with excellent selectivities over CYP11B1.
It is no doubt that the inhibition of CYP11B2 is a promising treatment for primary aldosteronism, hypertension, congestive heart failure, myocardial fibrosis and diabetic nephropathy. [7] The application of CYP11B2 inhibition can also be expanded to other indications because elevation of aldosterone levels is suspected as a side effect in breast cancer patients receiving aromatase (CYP19) In this study, we have shown that 1-phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols are a new class of potent and selective human aldosterone synthase inhibitors. The most active compound, the metatrifluoromethoxy substituted derivative 11, exhibits an IC 50 value of 14 nM and excellent selectivity over the highly homologous CYP11B1 (SF = 415). It shows no inhibition of CYP17 (< 5 % inhibition, c = 2 µM) and CYP19 (< 5 % inhibition, c = 500 nM) and a bioavailability after peroral application of about 20 %. This compound was chosen as a new lead compound in order to optimize pharmacokinetic parameters for further pharmacodynamic investigations in vivo. ) and subsequently substituted thiophenol (1.2 eq.) was added to a solution of 1b (1 eq.) in dry DMF under an atmosphere of nitrogen. The mixture was stirred at 100 °C until the conversion was complete (0.5 to 3 h, monitored by TLC). After cooling to room temperature, the crude mixture was partitioned between ethyl acetate and water and the aqueous layer was exhaustingly extracted with ethyl acetate.
Materials and Methods
Chemical and Analytical
The combined organic layers were washed with brine and dried over anhydrous MgSO 4 . Then, the solvents were removed under reduced pressure. The products were obtained after flash chromatography on silica gel (petroleum ether/ethyl acetate or CH 2 Cl 2 /methanol mixtures).
Procedure B.
[Fehler: Referenz nicht gefunden] m-CPBA (1 eq.) was added in portions to a solution of the sulfide (1 eq.) in CH 2 Cl 2 . The mixture was stirred at room temperature until the conversion was complete (0.5 to 3 h, monitored by TLC). Then, it was washed with saturated aqueous Na 2 CO 3 and subsequently with brine, before it was dried over anhydrous MgSO 4 . Evaporation of the solvents under reduced pressure and purification by flash chromatography on silica gel (CH 2 Cl 2 /methanol mixtures) afforded the sulfoxides.
1-(Phenylthio)-3-(pyridin-3-yl)naphthalen-2-ol (1a).
Compound 1a was obtained according to procedure A using 1b (530 mg, 1.50 mmol) and thiophenol (184 µl, 1.80 mmol) in DMF (15 ml) after flash chromatography (petroleum ether/ethyl acetate 3/1) as colorless solid (425 mg, 1.29 mmol, 86 %), Anal. C21H15NOS (C, H, N, O) 120.3, 122.8, 124.6, 125.2, 128.4, 129.1, 129.6,   129.9, 130,8, 131.7, 132.3, 134.0, 137.1, 142.8, 148.8, 150.1, 158 .0. MS m/z 346.01 (MH + ). Fluorophenylsulfinyl)-3-(pyridin-3-yl)naphthalen-2-ol (8) . -3-yl)-1-(3-(trifluoromethoxy) -3-yl)-1-(2-(trifluoromethoxy)phenylsulfinyl)naphthalen-2-ol (12) . Compound 12 was obtained according to procedure B using 12a (278 mg, 0.67 mmol) and m-CPBA (166 mg, 0.67 mmol) in CH 2 Cl 2 (10 ml -3-yl)-1-(4-(trifluoromethyl) -3-yl)-1-(3-(trifluoromethyl)phenylsulfinyl)naphthalen-2-ol (14) . 1-(3,5-Bis(trifluoromethyl)phenylsulfinyl)-3-(pyridin-3-yl)naphthalen-2-ol (19) . In vivo pharmacokinetics. The animal study was conducted in accordance with German animal welfare guidelines. Adult male Wistar rats (243-275 g) were housed in a temperature-controlled room (20-24 °C) and maintained in a 12 h light/12 h dark cycle. The animals were catheterized in the jugular vein 2-3 days prior to the blood sampling. They were fasted ~14-16 h before application and fed again 6 hours after application. Water was available ad libitum. Prior to the first blood sampling, the rats were connected to a counterbalanced system and tubing to perform blood sampling in the freely moving animal. Compound 11 was dissolved in PEG400/water (1:1), was administered intravenous (1 mg/kg, 2 ml/kg, 3 rats) or peroral (1 mg/kg, 5 ml/kg, 3 rats). At time 0, 11 was applied and blood samples (250 μl) were taken at different time points between 5 min and 24 h postdose. Plasma was harvested and kept at -20 °C until being assayed. HPLC-MS/MS analysis and quantification of the samples was carried out on a Surveyor HPLC system coupled with a TSQ Quantum (ThermoFisher) triple quadrupole mass spectrometer equipped with an electrospray ioninterface (ESI). The mean of absolute plasma concentrations (± SEM) was calculated for the three rats and the regression was performed on group mean values. The pharmacokinetic analysis was performed by applying a non-compartment model using the PK Solutions 2.0 software (Summit Research Services, Montrose, USA).
1-(4-Methoxyphenylthio)-3-(pyridin-3-yl)naphthalen-2-ol (2a)
.
1-(3-Methoxyphenylthio)-3-(pyridin-3-yl)naphthalen-2-ol (3a)
1-(2-Methoxyphenylthio)-3-(pyridin-3-yl)naphthalen-2-ol (4a)
1-(4-Methoxyphenylsulfinyl)-3-(pyridin-3-yl)naphthalen-2-ol (2). Compound
1-(3-Methoxyphenylsulfinyl)-3-(pyridin-3-yl)naphthalen-2-ol (3).
1-(4-Chlorophenylsulfinyl)-3-(pyridin-3-yl)naphthalen-2-ol (5)
1-(2-Chlorophenylsulfinyl)-3-(pyridin-3-yl)naphthalen-2-ol (7). Compound
1-(4-
3-(Pyridin
) after flash chromatography (CH 2 Cl 2 /methanol 98.5/1.5) as yellow solid (102 mg, 0.24 mmol, 38 %), Anal. C22H14F3NO3S (C, H, N, O), mp 118 °C. MS m/z 429.93 (MH + ).
Docking study
The CYP11B2 crystal (PDB ID: 4DVQ) was processed as described previously, [43] including the removal of redundant protein copies, substrate and water as well as the addition of hydrogens and partial charges. Ligand was built and its energy was minimized in the MMFF94s force field using MOE. The docking study was performed with GOLD in automatic active-site detection mode. Heme iron was defined as the origin of active-site with a radius of 19 Å. The distance between the sp2 hybrid N and the iron was constrained to 1.9 to 2.5 Å. 50 independent genetic algorithm iterations for each run were set.
The resulted poses were further analyzed according to fitness in MOE. in compound 1 (CCDC 936617). [24] 1
